Girard Partners’s Acadia Pharmaceuticals ACAD Stock Holding History

Girard Partners’s Portfolio ACAD Stock Details ACAD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-1,020	Closed	-$21K	–	242
2018 Q3	$21K	Buy	+1,020	New	+$16K	﹤0.01%	590

Other funds holding ACAD

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Girard Partners's ACAD Position: Q4 2018 in Review

Girard Partners sold out of Acadia Pharmaceuticals (ACAD) in Q4 2018, closing a stake of 1,020 shares — an estimated $21K sold.

Girard Partners first reported a position in ACAD in Q3 2018 and held it in 1 quarter. The position peaked at $21K in Q3 2018. 186 funds tracked by Wall St. Rank hold ACAD as of Q4 2018.

Girard Partners reported no remaining Acadia Pharmaceuticals position as of Q4 2018 after selling out during the quarter.
Girard Partners sold 1,020 Acadia Pharmaceuticals shares in Q4 2018, an estimated $21K.
Girard Partners first reported a position in Acadia Pharmaceuticals in Q3 2018 and held it in 1 quarter.
Girard Partners's Acadia Pharmaceuticals position peaked at $21K in Q3 2018.
186 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2018.

Based on Girard Partners's 13F filing for Q4 2018, filed 11 Feb 2019.